《逃逸小分子CCR5抑制剂所用的HIV-1的遗传学和表型分析》

  • 来源专题:艾滋病防治
  • 编译者: 李越
  • 发布时间:2005-04-16
  • We have described previously the generation of an escape variant of human immunodeficiency virus type 1 (HIV-1), under the selection pressure of AD101, a small molecule inhibitor that binds the CCR5 coreceptor (A. Trkola, S. E. Kuhmann, J. M. Strizki, E. Maxwell, T. Ketas, T. Morgan, P. Pugach, S. X. L. Wojcik, J. Tagat, A. Palani, S. Shapiro, J. W. Clader, S. McCombie, G. R. Reyes, B. M. Baroudy, and J. P. Moore, Proc. Natl. Acad. Sci. USA 99:395-400, 2002). The escape mutant, CC101.19, continued to use CCR5 for entry, but it was at least 20,000-fold more resistant to AD101 than the parental virus, CC1/85. We have now cloned the env genes from the the parental and escape mutant isolates and made chimeric infectious molecular clones that fully recapitulate the phenotypes of the corresponding isolates. Sequence analysis of the evolution of the escape mutants suggested that the most relevant changes were likely to be in the V3 loop of the gp120 glycoprotein. We therefore made a series of mutant viruses and found that full AD101 resistance was conferred by four amino acid changes in V3. Each change individually caused partial resistance when they were introduced into the V3 loop of a CC1/85 clone, but their impact was dependent on the gp120 context in which they were made. We assume that these amino acid changes alter how the HIV-1 Env complex interacts with CCR5. Perhaps unexpectedly, given the complete dependence of the escape mutant on CCR5 for entry, monomeric gp120 proteins expressed from clones of the fully resistant isolate failed to bind to CCR5 on the surface of L1.2-CCR5 cells under conditions where gp120 proteins from the parental virus and a partially AD101-resistant virus bound strongly. Hence, the full impact of the V3 substitutions may only be apparent at the level of the native Env complex.
  • 原文来源:http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=353740
相关报告
  • 《HIV对CCR5抑制剂的反应:强化而非转换》

    • 来源专题:艾滋病防治
    • 编译者:李越
    • 发布时间:2005-04-16
    • Treatment of HIV infection has been revolutionized by the development of potent inhibitors of critical viral enzymes, particularly the HIV-1 reverse transcriptase and protease (1). Appropriate combinations of such drugs (referred to as highly active antiretroviral therapy or HAART) markedly suppress viral replication in most treated persons, leading to significant restoration of immune system function. In the developed world, HAART is responsible for dramatic reductions in HIV-associated morbidity and mortality. However, the quest for improved therapies continues, because of problems that seriously limit the current HAART regimens, including toxic side effects, viral persistence, difficulties in adhering to treatment, high cost, and the emergence of drug-resistant escape variants. The resistance problem is particularly challenging because of the extraordinarily high HIV-1 mutation rate, and the ability of viral variants harboring resistance mutations in both reverse transcriptase and protease to continue replicating in vivo. The viral mutability provides a rationale for developing anti-HIV drugs that target components of the host cell machinery essential for viral replication, because such molecules would not mutate in the face of drug pressure. The cellular receptors involved in HIV-1 entry are receiving special attention, with numerous candidate inhibitors at various stages of clinical development . However, HIV-1 finds ways to escape such inhibitors. In a recent issue of PNAS, Trkola et al. analyze the mechanism by which HIV-1 escapes in vitro from a low molecular weight inhibitor targeted against the CCR5 coreceptor. The findings raise important questions not only about the clinical applications of this novel class of anti-HIV agents, but also about coreceptor usage in HIV-1 disease.
  • 《CC和CXC趋化因子对HIV-1复制的抑制是遗传亚型非依赖的》

    • 来源专题:艾滋病防治
    • 编译者:李越
    • 发布时间:2005-04-20
    • We have studied the breadth and potency of the inhibitory actions of the CC chemokines macrophage inhibitory protein 1α (MIP-1α), MIP-1β, and RANTES against macrophage-tropic (M-tropic) primary isolates of human immunodeficiency virus type 1 (HIV-1) and of the CXC chemokine stromal cell-derived factor 1α against T-cell-tropic (T-tropic) isolates, using mitogen-stimulated primary CD4+ T cells as targets. There was considerable interisolate variation in the sensitivity of HIV-1 to chemokine inhibition, which was especially pronounced for the CC chemokines and M-tropic strains. However, this variation was not obviously dependent on the genetic subtype (A through F) of the virus isolates. Peripheral blood mononuclear cell donor-dependent variation in chemokine inhibition potency was also observed. Among the CC chemokines, the rank order for potency (from most to least potent) was RANTES, MIP-1β, MIP-1α. Some M-tropic isolates, unexpectedly, were much more sensitive to RANTES than to MIP-1β, whereas other isolates showed sensitivities comparable to those of these two chemokines. Down-regulation of the CCR5 and CXCR4 receptors occurred in cells treated with the cognate chemokines and probably contributes to anti-HIV-1 activity. Thus, for CCR5, the rank order for down-regulation was also RANTES, MIP-1β, MIP-1α.